Please assess the completion status of the following clinical trial:

Trial Title: A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants who have completed TAK-385/CCT-101 study~Exclusion Criteria:~1. Participants who had an adverse event in TAK-385/CCT-101 study which makes continued administration of the study drug difficult~2. Participants who became unable to comply with the protocol due to onset of a new disease, symptom, finding, or aggravation of clinical laboratory findings~3. Participants in whom investigator deems that the study drug shows no efficacy based on the level of pain, menstruation status, and the status of analgesic drug intake in TAK-385/CCT-101 study, or that study continuation represents an unacceptable risk~4. Participants in whom investigator deems that study continuation is difficult due to the occurrence of low estrogen symptoms in TAK-385/CCT-101 study which were attributed to the pharmacological effects of the study drug taking into account the level and frequency of the adverse events etc. as well as the risk-benefit of participants.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- TAK-385 10 mg QD (Type: EXPERIMENTAL): None
- TAK-385 20 mg QD (Type: EXPERIMENTAL): None
- TAK-385 40 mg QD (Type: EXPERIMENTAL): None
- Leuplin (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).